References
- Berman RM, Narasimhan M, Sanacora G, et al. (2000). A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 47:332–7.
- Chaki S, Ago Y, Palucha-Paniewiera A, et al. (2013). mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 66:40–52.
- Connolly KR, Thase ME. (2012). Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 17:105–26.
- Duman RS, Li N, Liu RJ, et al. (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62:35–41.
- Garner RC. (2010). Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2:429–40.
- Gobburu JV, Holford NH. (2001). Vz, the terminal phase volume: time for its terminal phase? J Biopharm Stat 11:373–5.
- Ings RM. (2009). Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1:1293–305.
- Krystal JH, Sanacora G, Duman RS. (2013). Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–41.
- Lappin G, Rowland M, Garner RC. (2006). The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2:419–27.
- Lappin G, Wagner CC, Langer O, van de Merbel N. (2009). New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis 1:357–66.
- Licznerski P, Duman RS. (2013). Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 251:33–50.
- Maeda K, Sugiyama Y. (2011). Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev 63:532–8.
- Manji HK, Quiroz JA, Sporn J, et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53:707–42.
- Nemeroff CB. (2007). Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68:17–25.
- Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203.
- Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metabol Rev 39:17–43.
- Rubin GM, Waschek JA, Pond SM, et al. (1987). Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J Pharmacokinet Biopharm 15:615–31.
- Sarapa N, Hsyu PH, Lappin G, Garner RC. (2005). The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45:1198–205.
- Zarate. CA, Jr Singh JB, Carlson PJ, et al. (2006a). A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–64.
- Zarate. CA, Jr Singh JB, Quiroz JA, et al. (2006b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153–5.
- Zarate. CA Jr, Tohen M. (2004). Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 161:169–71.